DPP4

In a report published Tuesday, Bank of America analyst Colin Bristow commented on Merck & Co., Inc. (NYSE: MRK)'s announcement of top-line results for the TECOS trial, noting that the study met its primary endpoint of non-inferiority versus placebo for the composite CV endpoint. The...